Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Oktober 2025

Genmab — Oktober 2025

Planlagt Fastgjort Låst Flyttet Genmab
427 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #366

    ESMO 2025 posters via https://www.genmabmedicalaffairs.com/congress?filv1=25 - Rinatabart Sesutecan & Tisotumab Vedotin

    1 Reply Last reply
    0
    • P Offline
      P Offline
      Pensionisten
      wrote on sidst redigeret af
      #367

      Michael Novod, Nordea, går til Novo, iflg. Børsen...

      1 Reply Last reply
      0
      • J Offline
        J Offline
        JKY_VH
        wrote on sidst redigeret af
        #368

        Jep han skal stå i spidsen for IR

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #369

          Takeda signs deal worth up to $11.4bn with Innovent for cancer drug hopefuls -$1.2bn upfront, while Innovent will also be eligible to cash in on up to $10.2bn worth of milestone payments. https://www.pharmaceutical-technology.com/news/takeda-innovent-oncology-licensing-deal-11-4bn-adc-bispecifics/?cf-view

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #370

            Heavy deals nowadays

            1 Reply Last reply
            0
            • J Offline
              J Offline
              JKY_VH
              wrote on sidst redigeret af
              #371

              Ja Genmabs investering ligner jo den rene klatskilling:-)

              1 Reply Last reply
              0
              • B Offline
                B Offline
                bibob
                wrote on sidst redigeret af
                #372

                Ja, Jay.

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bibob
                  wrote on sidst redigeret af
                  #373

                  @JKY. . Ja , men man kan håbe at en klatskilling er bedre end en fejl disponering. 😞

                  1 Reply Last reply
                  0
                  • J Offline
                    J Offline
                    JKY_VH
                    wrote on sidst redigeret af
                    #374

                    ja absolut:-)

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #375

                      Roche presentation Q3 2025 https://assets.roche.com/f/176343/x/a22e1c7d2f/irp251023.pdf

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        LP90
                        wrote on sidst redigeret af
                        #376

                        Godmorgen 🙂

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #377

                          Godmorgen

                          1 Reply Last reply
                          0
                          • B Offline
                            B Offline
                            bibob
                            wrote on sidst redigeret af
                            #378

                            God morgen. 🙂

                            1 Reply Last reply
                            0
                            • SolsenS Offline
                              SolsenS Offline
                              Solsen
                              wrote on sidst redigeret af
                              #379

                              Thanks EL. Columvi 200 mln, Ocrevy impressing +5 bn and still ca 1 bn in Rituxan

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #380

                                Ocrevus has become a huge succes. Damn GSK !

                                1 Reply Last reply
                                0
                                • W Offline
                                  W Offline
                                  w
                                  wrote on sidst redigeret af
                                  #381

                                  at være
                                  first mover, er tydeligvis vigtig

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #382

                                    Look fw to Novartis Q3 and Kesimpta sales.

                                    1 Reply Last reply
                                    0
                                    • SolsenS Offline
                                      SolsenS Offline
                                      Solsen
                                      wrote on sidst redigeret af
                                      #383

                                      @w yes its important

                                      1 Reply Last reply
                                      0
                                      • SolsenS Offline
                                        SolsenS Offline
                                        Solsen
                                        wrote on sidst redigeret af
                                        #384

                                        And Roche salesforce are clever.

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #385

                                          So for Q1 Q2 Q3 2025: Columvi

                                          60 , 63 , 79 Lunsumio 21 , 27 , 29 Ocrevus 1778 , 1728 , 1690 all in CHF -if i calculate correctly...

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper